Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05833360 · ClinicalTrials.gov registry record
Prospective Study of oncRNA Stratification of Cancer by Size and Stage
A clinical trial of Cancer, sponsored by Exai Bio.
- Recruiting
- Registry status
- 2,400
- Enrollment target
- 2
- Study locations
NCT05833360 is a study of Cancer that is actively recruiting participants, run by Exai Bio. The registered enrollment target is 2,400 participants, below the 3,487-participant average among 615 other Cancer trials with a reported enrollment target (31% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT05833360, a study of Cancer, is actively recruiting participants, sponsored by Exai Bio.
- RECRUITING
- Registry status
- 2,400 participants
- Enrollment target
- 2
- Study locations
Study Summary
Cancer strikes about one in three women and one in two men in the U.S. and more than 600,000 die from it each year. The best chance to reduce these numbers and save lives is through early detection and intervention. The investigators are developing a blood test to detect cancer from a simple blood draw also referred to as a liquid biopsy. This test is based on orphan non-coding RNAs (oncRNAs) that are abundant in the blood of patients with cancer and largely absent in people without cancer. Using artificial intelligence (AI) and machine learning (ML) investigators are able to interpret the thousands of oncRNAs found in the blood of patients with cancer by identifying unique, cancer-specific patterns. oncRNA patterns can be used to detect several types of cancer and detect cancer at the earliest stages. This is a prospective, observational study to collect blood samples and medical information from participants with and without cancer to represent the population in the USA. The investigators have designed the study to include participants without cancer, participants with conditions that are a predisposition for cancer, participants with pre-malignant lesions, and participants with cancer. Patients with a wide variety of cancers are going to be included i.e. bladder, breast, colorectal, esophageal, gastric, kidney, liver, lung, ovarian, pancreatic, prostate, and uterine cancer. Each participant will be asked to donate a small blood sample and to share their medical information. The participant's medical information will be updated during the course of the study. The blood will be tested for oncRNA. The objective is to create a blood repository and associated medical database to develop a blood test for cancer, for different cancer types. The study is designed to be inclusive and represent the population in America. If this study is successful, the results will enable a world where cancer can be detected early with a simple blood test and diagnosed accurately, wit
Conditions Studied
Interventions
- DEVICE Exai oncRNA blood test
Study Locations (2)
California
- Exai Bio Inc. - Palo Alto
Nevada
- Renown Health - Reno
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,400 participants |
| Start Date | 2023-07-14 |
| Est. Completion | 2030-07-14 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05833360
The ClinicalTrials.gov registry entry for NCT05833360 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 2,400 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,487-participant average among 615 other Cancer trials with a reported enrollment target (31% lower). The listed sponsor is Exai Bio, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cancer appearing as the primary indexed condition, and to 1 intervention - of which Exai oncRNA blood test is the first listed.
NCT05833360 reports 2 study locations spanning 2 distinct geographic areas - top geographies include California, Nevada.
Frequently Asked Questions
What is clinical trial NCT05833360 about?
NCT05833360 is a clinical study titled "Prospective Study of oncRNA Stratification of Cancer by Size and Stage". Cancer strikes about one in three women and one in two men in the U.S. and more than 600,000 die from it each year. The best chance to reduce these numbers and save lives is through early detection and intervention. The investigators are developing a blood test to detect cancer from a simple blood ...
What is the current status of trial NCT05833360?
This trial is currently recruiting. The enrollment target is 2,400 participants. The study started on 2023-07-14. Estimated completion is 2030-07-14.
What conditions does trial NCT05833360 study?
This clinical trial studies the following conditions: Cancer.
What interventions are being tested in trial NCT05833360?
The interventions under investigation include: Exai oncRNA blood test (DEVICE).
Who is sponsoring clinical trial NCT05833360?
This trial is sponsored by Exai Bio, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05833360 being conducted?
This trial has 2 study locations across California, Nevada. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Registry Study to Evaluate the Clinical Outcome of Cancer Patients and Benign Diseases Treated with Radiation
RECRUITING
-
Treatment of Immune Checkpoint Inhibitor-related Diarrhea and/ or Colitis With Ustekinumab in Cancer Patients
RECRUITING · Phase 2
-
IMPACT (IMproving Proactive Approaches for Cancer Survivors' Mental Health Treatment)
RECRUITING · NA
-
A Natural History Study of Metabolic Sizing in Health and Disease
RECRUITING
-
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
RECRUITING · Phase 1
-
Long-Term Follow-Up of Recipient of Gene Transfer Research
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.